Cargando…

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment

We aimed to investigate the dynamic changes of gene expression profiles and immune microenvironment linked to resistance to cetuximab-based treatments in patients with metastatic colorectal cancer (mCRC). A total of 106 patients with RAS-wild type mCRC who were treated with cetuximab-based treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyung-Don, Kim, Sun Young, Kim, Jihun, Kim, Jeong Eun, Hong, Yong Sang, Han, Buhm, Tak, Eunyoung, Ryu, Yeon-Mi, Kim, Sang-Yeob, Kim, Tae Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803829/ https://www.ncbi.nlm.nih.gov/pubmed/35102212 http://dx.doi.org/10.1038/s41598-022-05694-x

Ejemplares similares

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study
por: Cho, Hyungwoo, et al.
Publicado: (2022)

Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer
por: Kim, Dalyong, et al.
Publicado: (2017)

Immune Profile of BRAF-Mutated Metastatic Colorectal Tumors with Good Prognosis after Palliative Chemotherapy
por: Kim, Jeong Eun, et al.
Publicado: (2022)

Clinicogenomic Characteristics and Treatment of Young-Onset Colorectal Cancer Patients Treated With Palliative Therapy in Real-World Practice
por: Jeong, Hyehyun, et al.
Publicado: (2022)

Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours
por: Yoo, Changhoon, et al.
Publicado: (2019)

Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients
por: Park, Jin Hyun, et al.
Publicado: (2022)

Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer
por: Park, Seong Hye, et al.
Publicado: (2019)

Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
por: Kim, Jwa Hoon, et al.
Publicado: (2022)

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair–Deficient/Microsatellite Instability–High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer
por: Kim, Jwa Hoon, et al.
Publicado: (2020)

Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling
por: Chang, Jae Won, et al.
Publicado: (2015)

Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability–High Colon Cancer
por: Hyung, Jaewon, et al.
Publicado: (2022)

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab
por: Lee, Sang-Kyu, et al.
Publicado: (2018)

Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
por: Kim, Sang-A, et al.
Publicado: (2021)

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2016)

A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
por: Koo, Dong Hoe, et al.
Publicado: (2007)

Chitinase 3-Like 1 Contributes to Food Allergy via M2 Macrophage Polarization
por: Kim, Eun Gyul, et al.
Publicado: (2020)

Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma
por: Kim, Hyungjoo, et al.
Publicado: (2017)

Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
por: Bray, Steven M., et al.
Publicado: (2019)

CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model
por: Jung, Jae Yun, et al.
Publicado: (2021)

Dysadherin awakens mechanical forces and promotes colorectal cancer progression
por: Park, So-Yeon, et al.
Publicado: (2022)

Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan
por: Kim, Seung Tae, et al.
Publicado: (2015)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Analysis of Syndecan-2 Methylation in Bowel Lavage Fluid for the Detection of Colorectal Neoplasm
por: Park, Young Sook, et al.
Publicado: (2018)

Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines
por: Kim, Sujin, et al.
Publicado: (2019)

Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab: A single-institutional experience
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Validation of the Korean Stroop Test in Diagnosis of Minimal Hepatic Encephalopathy
por: Yoon, Eileen L., et al.
Publicado: (2019)

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021)

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
por: Jang, Min Hye, et al.
Publicado: (2012)

High prevalence of TP53 loss and whole-genome doubling in early-onset colorectal cancer
por: Kim, Jeong Eun, et al.
Publicado: (2021)

Roles of heterogenous hepatic macrophages in the progression of liver diseases
por: Lee, Kyeong-Jin, et al.
Publicado: (2022)

Characterization of Binding and Phagocytosis of Oxidatively Damaged Erythrocyte to Macrophage
por: Ko, Hong Sook, et al.
Publicado: (2002)

Single particle tracking-based reaction progress kinetic analysis reveals a series of molecular mechanisms of cetuximab-induced EGFR processes in a single living cell
por: Kim, Do-Hyeon, et al.
Publicado: (2017)

Epigenetic Silencing of CHOP Expression by the Histone Methyltransferase EHMT1 Regulates Apoptosis in Colorectal Cancer Cells
por: Kim, Kwangho, et al.
Publicado: (2022)

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2017)

Hepatic resection after neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer: need for cautious planning
por: Kim, Young Il, et al.
Publicado: (2019)

Stratifin (SFN) regulates lung cancer progression via nucleating the Vps34‐BECN1‐TRAF6 complex for autophagy induction
por: Kim, Ji Young, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p96dqcls1thud5gsd2csvpq41h